Abstract
BackgroundCarcinoma of unknown primary (CUP) is a diagnostic and therapeutic challenge; correct diagnostic approach results in better outcomes in patients with brain metastasis. Whole body 18 F-FDG PET/CT is a helpful modality to detect the origin of primary tumor and assess metastasis in the rest of the body. We assessed the value of PET/CT in detection of unknown primary in 39 patients with brain metastases as initial presentation and detected its impact on their overall survival.ResultsPET/CT could correctly detected the primary tumor in 49% of patients which occurred mainly in the lung, 63% of patients had additional extracerebral metastatic sites mostly in lymph nodes. Specificity, sensitivity, and accuracy of PET/CT in CUP patients were 95%, 79%, and 87%, respectively. No significant difference was noticed in estimated overall survival time between patients with an identified primary tumor and patients with unidentified primary tumor.ConclusionPET–CT was a helpful non-invasive imaging modality in detecting primary in CUP patients with metastatic brain lesion. It helped in the diagnosis of unexpected extracerebral metastatic lesions. However, the identification of the primary tumor by PET/CT has no significant prognostic effect on patient overall survival.
Highlights
Carcinoma of unknown primary (CUP) is a diagnostic and therapeutic challenge; correct diagnostic approach results in better outcomes in patients with brain metastasis
There was no significant difference between patients with PET/18F-Fluordesoxyglucose position emission tomography (CT) lesions regarding gender and age (P = 0.362, P = 0.075)
Diagnostic performance of PET/CT in the detection of primary tumor In this study, we found that PET/CT showed specificity, sensitivity, and accuracy PET/CT in detection of primary tumor as 95%, 79%, and 87%, respectively
Summary
Carcinoma of unknown primary (CUP) is a diagnostic and therapeutic challenge; correct diagnostic approach results in better outcomes in patients with brain metastasis. We assessed the value of PET/CT in detection of unknown primary in 39 patients with brain metastases as initial presentation and detected its impact on their overall survival. PET/CT has been proven to be more accurate than contrastenhanced CT or MRI alone in the identification of the primary tumor site, tumor extent, local-regional, and distant metastases. This helps in selection of a more suitable and site-specific therapy and follow-up associated with a better overall survival and improved treatment outcome [4]
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have